Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT05268120

MRSA Decolonization in Complicated Carriage

Led by Leiden University Medical Center · Updated on 2025-03-06

211

Participants Needed

1

Research Sites

301 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Multicenter open-label cluster randomized controlled trial determining the superiority of doxycycline-rifampicin compared to trimethoprim-rifampicin for the decolonization treatment of complicated MRSA carriership.

CONDITIONS

Official Title

MRSA Decolonization in Complicated Carriage

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 6518 years
  • Complicated MRSA carriership defined by any of the following: MRSA at sites other than the nose, active MRSA infection, mupirocin resistance in vitro, active skin lesions, presence of foreign material connecting internal body site to outside, or previous failure of decolonization treatment
  • Ability to provide informed consent for the use of their data
Not Eligible

You will not qualify if you...

  • Presence of any intravenous access, urinary catheters, or drains
  • Failure of previous decolonization attempt for complicated MRSA carriage
  • Allergy or contraindication to doxycycline, rifampicin, or trimethoprim
  • Previous participation in this study
  • Pregnancy

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

LUMC

Leiden, Netherlands

Actively Recruiting

Loading map...

Research Team

A

Annette Westgeest, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

CROSSOVER

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here